Metabolomics and microbiome profiling as biomarkers in obstructive sleep apnoea: a comprehensive review

Introduction Obstructive sleep apnoea (OSA) is a common sleep disorder with a high social and economic burden. Thus, early prediction and diagnosis of OSA are important. Changes in metabolism and the microbiome may serve as biomarkers for OSA. Herein, we review the literature on the metabolomic and microbiome changes associated with OSA, and identify the metabolites and microorganisms involved. Methods We searched the PUBMED and EMBASE electronic databases using the following terms: obstructive sleep apnea, OSA, sleep disordered breathing, SDB, intermittent hypoxia, sleep fragmentation, and either metabolomics or microbiome. In total, 273 papers were identified, of which 28 were included in our study. Results Changes in the levels of certain metabolites related to fatty acid, carbohydrate and amino acid metabolism were associated with the incidence of OSA. The diversity and abundance of microflora, particularly Firmicutes and Bacteroidetes, were altered in humans and rodents with OSA. Conclusions Certain changes in metabolism and the microbiota play an integral role in the pathophysiology of OSA and OSA-induced cardiovascular complications. Metabolomic and microbiome biomarkers shed light on the pathogenesis of OSA, and facilitate early diagnosis and treatment.

Automated summary

This study reviewed the changes in metabolomic and microbiome associated with obstructive sleep apnoea (OSA) and identified specific metabolites and microorganisms involved. The findings suggest that certain changes in metabolism and microbiota may play a key role in the pathophysiology of OSA and OSA-induced cardiovascular complications. Metabolomic and microbiome biomarkers provide insights into the pathogenesis of OSA and help in early diagnosis and treatment.